Bacterial Polysaccharide Immune Globulin (BPIG) is prepared from donors immunized with H. influenzae b(Hib) pneumococcal and meningococcal vaccines. With previous NIAID support, BPIG has been prepared, characterized, and shown to be efficacious in preventing bacteremic Hib infections in high risk Apache infants. With separate funding from NIAID, a clinical trial to evaluate efficacy against systemic pneumococcal infections is underway and a demonstration project to introduce BPIG into general use to prevent HIB infections in Eskimo infants of the Yukon-Kuskokwim Delta is scheduled to begin in May 1989. The proposed studies are designed to improve further the methods for preparing BPIG, to characterize more precisely the anticapsular antibodies (Abs) in immunized adults and in BPIG, and to develop better standardized assays for Hib, pneumococcal, and meningococcal polysaccharide (Ps) Abs. In order to maximize the Ab response of plasma donors to Ps antigens, we will immunize them with more immunogenic Ps-protein conjugate vaccines and evaluate the quantity and quality of the IgG Ab produced. Alternative and potentially inexpensive methods to enrich Ps Abs will be explored by determining whether affinity chromatography with oligosaccharides can be used to purify Hib Ab from the globulin of unimmunized donors. The pharmacology of BPIG containing higher concentrations of Ab to Hib and to carrier proteins will be examined in high risk groups. Combination passive-active immunization regimens utilizing BPIG and Hib and pneumococcal conjugate vaccines will be examined. Standardized ELISA assays for Ab to Hib, pneumococci and meningococci will be developed and calibrated. The activities of Hib Ps Abs differing in IgG subclass, light chain composition, and G2m(n) allotype will be examined in binding assays, functional assays and in experimental infection. The role of Ab affinity and rheumatoid factors in altering Hib Ps Ab activities in these assays will also be examined. These closely interrelated studies will enhance our basic understanding of the human Ab response to Ps and the functional mechanisms underlying Ab binding to Ps. In addition, they will result in the development of improved methods for immunoprophylaxis of encapsulated bacterial infections in high risk groups. Groups that might benefit from passive immunization include American Indian and Alaskan Eskimo infants, children on cancer chemotherapy with asplenia, sickle cell disease or B cell immunodeficiencies, and secondary contacts of Hib or meningococcal infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI018125-09
Application #
3127704
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1981-08-01
Project End
1994-11-30
Budget Start
1989-12-01
Budget End
1990-11-30
Support Year
9
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Perez-Perez, Guillermo I; Sack, R Bradley; Reid, Raymond et al. (2003) Transient and persistent Helicobacter pylori colonization in Native American children. J Clin Microbiol 41:2401-7
Englund, J A; Glezen, W P; Thompson, C et al. (1997) Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr Infect Dis J 16:1122-30
Nahm, M H; Siber, G R; Olander, J V (1996) A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides. J Infect Dis 173:113-8
Saladino, R A; Stack, A M; Thompson, C et al. (1996) High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis. Crit Care Med 24:1203-7
Samore, M H; Siber, G R (1996) Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Vaccine 14:290-7
Nelson, D; Kuppermann, N; Fleisher, G R et al. (1995) Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats. Crit Care Med 23:92-8
Englund, J A; Glezen, W P; Turner, C et al. (1995) Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 171:99-105
Saladino, R; Garcia, C; Thompson, C et al. (1994) Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis. Circ Shock 42:104-10
Kuppermann, N; Nelson, D S; Saladino, R A et al. (1994) Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. J Infect Dis 170:630-5
Garcia, C; Saladino, R; Thompson, C et al. (1994) Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit Care Med 22:1211-8

Showing the most recent 10 out of 42 publications